ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,996.66
1.00%
Dow Jones
43,487.83
0.78%
US Dollar vs MXN
20.6958
0.93%
Brent Oil
79.425
0.26%
Bitcoin
102,457.98
0.42%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Calithera Biosciences Inc (CALA) Cotización

Calithera Biosciences Inc

Calithera Biosciences Inc (CALA)

Calithera Biosciences Inc (CE)
0.20
0.00
(0.00%)
Cerrado 20 Enero 3:00PM
Delayed by 15 minutes
0.00
0.00
(0.00%)
Fuera de horario: -
Delayed by 15 minutes

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Estadísticas y detalles clave

Último Precio
0.20
Postura de Compra
0.16
Postura de Venta
0.35
Volume Operado de la Acción
-
0.00 Rango del Día 0.00
0.00 Rango de 52 semanas 0.00
Capitalización de Mercado [m]
974.499k
Precio Anterior
0.20
Precio de Apertura
-
Hora
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
-
Acciones en circulación
4,872,497
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.05
Beneficio por acción (BPA)
-4.37
turnover
-
Beneficio neto
-21.29M

Acerca de Calithera Biosciences Inc

Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the US. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumo... Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the US. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its lead product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.calithera.com
Sede
Wilmington, Delaware, USA
Fundado
-

CALA Últimas noticias

Más noticias

Calithera Biosciences Announces Update on Complete Liquidation and Dissolution

SOUTH SAN FRANCISCO, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC: “CALA”). Calithera Biosciences, Inc. (the “Company”) announced that it was unable to achieve a...

29 Junio 2023
GlobeNewswire Inc.

Calithera Biosciences Announces Update on Complete Liquidation and Dissolution

SOUTH SAN FRANCISCO, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC: CALA) (the “Company”) announced that it intends to hold a special meeting of stockholders on or...

19 Mayo 2023
GlobeNewswire Inc.

Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), today announced that its Board of Directors has determined, after extensive...

09 Enero 2023
GlobeNewswire Inc.

Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its...

14 Noviembre 2022
GlobeNewswire Inc.

Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced...

08 Noviembre 2022
GlobeNewswire Inc.

Calithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung Cancer

SOUTH SAN FRANCISCO, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that...

03 Octubre 2022
GlobeNewswire Inc.

Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that...

06 Septiembre 2022
GlobeNewswire Inc.

Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its...

15 Agosto 2022
GlobeNewswire Inc.

Calithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced...

08 Agosto 2022
GlobeNewswire Inc.

Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences

-- Overview of phase 2 study evaluating SYK inhibitor mivavotinib in patients with relapsed/refractory non-GCB (ABC) diffuse large B-cell lymphoma -- -- First data from phase 1...

13 Julio 2022
GlobeNewswire Inc.
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

CALA - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Calithera Biosciences?
El precio actual de las acciones de Calithera Biosciences es US$ 0.20
¿Cuántas acciones de Calithera Biosciences están en circulación?
Calithera Biosciences tiene 4,872,497 acciones en circulación
¿Cuál es la capitalización de mercado de Calithera Biosciences?
La capitalización de mercado de Calithera Biosciences es USD 974.5k
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Calithera Biosciences?
Calithera Biosciences ha negociado en un rango de US$ 0.00 a US$ 0.00 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Calithera Biosciences?
El ratio precio/beneficio de Calithera Biosciences es -0.05
¿Cuál es la moneda de reporte de Calithera Biosciences?
Calithera Biosciences presenta sus resultados financieros en USD
¿Cuál es el último beneficio anual de Calithera Biosciences?
El último beneficio anual de Calithera Biosciences es USD -21.29M
¿Cuál es la dirección registrada de Calithera Biosciences?
La dirección registrada de Calithera Biosciences es 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de Calithera Biosciences?
La dirección del sitio web de Calithera Biosciences es www.calithera.com
¿En qué sector industrial opera Calithera Biosciences?
Calithera Biosciences opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
BTCTBTC Digital Ltd
US$ 8.2697
(73.73%)
61.45M
BDMDBaird Medical Investment Holdings Ltd
US$ 8.80
(62.36%)
18.63M
CRKNCrown Electrokinetics Corporation
US$ 0.1235
(54.96%)
764.86M
NUKKNukkleus Inc
US$ 29.97
(45.98%)
19.09M
GSITGSI Technology
US$ 3.97
(44.36%)
87.7M
DOGZDogness International Corporation
US$ 18.23
(-58.77%)
740.45k
ORKTOrangeKloud Technology Inc
US$ 3.02
(-24.88%)
21.08M
PMAXPowell Max Ltd
US$ 0.6364
(-23.31%)
4.17M
LGCBLinkage Global Inc
US$ 0.2876
(-22.27%)
890.66k
YYAIConnexa Sports Technologies Inc
US$ 0.8299
(-20.20%)
602.48k
CRKNCrown Electrokinetics Corporation
US$ 0.1235
(54.96%)
764.86M
GCTKGlucoTrack Inc
US$ 0.0852
(15.45%)
465.22M
RIMEAlgorhythm Holdings Inc
US$ 0.0406
(-4.02%)
387.23M
TGLTreasure Global Inc
US$ 0.2459
(14.75%)
267.1M
NVDANVIDIA Corporation
US$ 137.71
(3.10%)
201.4M

CALA Discussion

Ver más
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 2 años hace
maybe soon will see something
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 2 años hace
maybe soon will see something
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 2 años hace
looking close
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 2 años hace
cala soon something
👍️0
Renee Renee 2 años hace
CALA delisted from the Nasdaq to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions
👍️0
kzivann kzivann 2 años hace
CALA dissolving. https://quantisnow.com/insight/3950020
👍️0
Mr. Zen Mr. Zen 2 años hace
Calithera continued to advance multiple vacuolar protein sorting-associated protein 4A (VPS4A) and VPS4B inhibitors through lead optimization and plans to share updates on this program by the end of 2022.
👍️0
Nealio Nealio 2 años hace
CALA - continues upward. 100% gain in last month, very good swing play. Drug data was good...float is very low at 4.X M shares.
👍️0
Nealio Nealio 2 años hace
CALA in play! Drug data and earnings report. Should move even higher on this news.
👍️0
Nealio Nealio 2 años hace
Chart looks very good atm.
👍️0
Nealio Nealio 2 años hace
Could be the start of a big run; or not. We shall see; with recent good news, I like the chances. Good luck to all!
👍️0
ttottip ttottip 3 años hace
Yes.
👍️0
ttottip ttottip 3 años hace
Good morning all! Hoping for a reversal today.
👍️0
ttottip ttottip 3 años hace
I'm not hesitating to buy at these levels!
👍️0
bandit007 bandit007 3 años hace
Took a few here. $CALA
👍️0
kzivann kzivann 3 años hace
Moving after hours.

CALA
👍️0
crudeoil24 crudeoil24 3 años hace
Calithera Biosciences shares are trading higher after Ladenburg Thalmann initiated coverage on the stock with a Buy rating and a $4 price target.

CALA
👍️0
TheFinalCD TheFinalCD 3 años hace
big move 45-74


$CALA
👍️0
glens0 glens0 3 años hace
$CALA .58 w/ $3 price upgrade out by Leerink
👍️0
Eagle1 Eagle1 3 años hace
Thank you
👍️0
crudeoil24 crudeoil24 3 años hace
Company discontinued its KEAPSAKE clinical trial.
👍️0
Eagle1 Eagle1 3 años hace
Hi why the drop here?
👍️0
0210 0210 3 años hace
Calithera Biosciences CALA Q3 EPS $(0.15) Beats $(0.23) Estimate, Sales $6.75M, and a 53.13 percent increase over losses of $(0.32) per share from the same period last year.

4:42 pm ET November 9, 2021 (Benzinga)
Calithera Biosciences (NASDAQ:CALA) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.23) by 34.78 percent. This is a 53.13 percent increase over losses of $(0.32) per share from the same period last year. The company reported $6.75 million in sales this quarter.
👍️0
0210 0210 3 años hace
right-on-the-money...-54% to $0.86-0.87, from $1.90 on 21x dmav (of only 1,082,848 daily moving average volume).

SOURCE: https://ih.advfn.com/stock-market/NASDAQ/calithera-biosciences-CALA/historical

👍️0
willlbone willlbone 3 años hace
Bid at 60% drop.
👍️0
TheFinalCD TheFinalCD 3 años hace
$CALA -40%

Calithera Biosciences, Inc. | Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial

https://ir.calithera.com/news-releases/news-release-details/calithera-biosciences-announces-decision-discontinue-keapsake
👍️0
Elgordo84 Elgordo84 4 años hace
I’m expecting earnings to be on the up tomorrow
Let’s go $CALA
👍️0
Elgordo84 Elgordo84 4 años hace
Looks like no one is paying attention
$CALA I guess is you and me!!!
Perfect for the run
While no one is watching.......
👍️0
Elgordo84 Elgordo84 4 años hace
Ok hello $CALA
I LIKE WHAT I SEE HERE!!!!
Let’s take this for a ride...
$CALA LETS GO —————>

👍️0
trade-stock000 trade-stock000 4 años hace
Cala when is the data due date? Thx
👍️0
oaps222 oaps222 4 años hace
Thanks for the info.
Geez~~, what a move. I wish I knew it last Thursday! LOL

In any event, congratulations, if you already got in ARTL!
👍️0
trade-stock000 trade-stock000 4 años hace
A-R-T-L is the one to watch (: PT $8-10
Add on correction price, read few post over there abt data and cocrystal CBD molecules. Apart from that it's focused on Lipid therapy the next frontier in Oncology.
👍️0
oaps222 oaps222 4 años hace
Very good point, but be careful. The market is crazy. I can see some (big?) corrections in the near future.
👍️0
oaps222 oaps222 4 años hace
From the recent 13G Filings, Adage Capital has reported its 4,000,000 shares of CALA (5.67% ownership) on Jan 13, 2021.
👍️0
trade-stock000 trade-stock000 4 años hace
Yeah but in Jan that was not much of an update, that´s why stock plummeted, company needs more time.

Jan option price rose becoz of that reason, now fade out. Will visit this ticker later, for now it´s waste of cash esp when whole market is running nut
👍️0
oaps222 oaps222 4 años hace
Was it on Jan 15-17, not Feb 15-17?
http://www.calithera.com/wp-content/uploads/2021/01/Arginase-1158-203-Poster.pdf
👍️0
trade-stock000 trade-stock000 4 años hace
IV surges in the event of future price move. $5 call for Feb 19 it seems someone very bullish abt this stock and bot calls. Article u cited it's from Jan-13th, today its 13th Feb (:, unless next week something comes out which is highly unlikely.
👍️0
oaps222 oaps222 4 años hace
I was doing a DD on CALA and found the following. I don't quite understand it. Can you share your thoughts on this?
"Implied Volatility Surging for Calithera Biosciences (CALA) Stock Options"

https://finance.yahoo.com/news/implied-volatility-surging-calithera-biosciences-134001483.html
👍️0
trade-stock000 trade-stock000 4 años hace
2.42 or lower test first before go up i hope
👍️0
trade-stock000 trade-stock000 4 años hace
CALA on Feb 15-17 presenting Biliary-Tract Cancer-Data-could do-vroomvroom
👍️0
jondoeuk jondoeuk 4 años hace
ASH abstract https://ash.confex.com/ash/2020/webprogram/Paper137266.html
👍️0
ClayTrader ClayTrader 5 años hace
* * $CALA Video Chart 12-23-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
cashbyers cashbyers 5 años hace
9.5M block trade today @ $4.45.. 17% stake or $42M investment...
👍️0
ClayTrader ClayTrader 5 años hace
* * $CALA Video Chart 11-19-19 * *

Link to Video - click here to watch the technical chart video

👍️0
jonny_red jonny_red 5 años hace
4 Penny Stocks To Watch In November After Latest Milestones

$GTBP $CALA $AVDL $BLCM

https://www.transparenttraders.me/2019/11/4-penny-stocks-to-watch-in-november.html
👍️0
cashbyers cashbyers 5 años hace
Long CALA @ $2.60
👍️0
buypumps buypumps 5 años hace
Conference call Monday also. Could push to 3.90 area.
👍️0
Zmill Zmill 6 años hace
TA of CALA https://msmoneymoves.com/2019/07/12/calithera-initiates-potential-buying-opportunity/
👍️0
CashBowski CashBowski 6 años hace
CALA going to close the gap today.
👍️0
Zmill Zmill 6 años hace
Research mentioning CALA https://wordpress.com/block-editor/post/msmoneymoves.com/11262
👍️0

Su Consulta Reciente

NASDAQ
CALA
Calithera Biosciences
LSE
0IF4
Eastman Kodak
BIT
F29238
Vontobel Financial Produ...
LSE
0A3L
Vertex
BOV
FDXB34R
Fedex
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados